InterVenn Biosciences logo

Venn BioSciences Corp.

Biotechnology

InterVenn Biosciences Stock

InterVenn Biosciences is a company that specializes in the development of novel diagnostic tests for early detection and diagnosis of cancer and other diseases. InterVenn's flagship product is the glycoproteomics-based liquid biopsy test, which is a non-invasive blood test that can detect early-stage cancers and other diseases.

Management Team

Daniel Hommes, M.D., Ph.D. Chief Medical Officer
Jason Myers, Ph.D. President
Brian Hogan Chief Financial Officer
Dan Serie Chief Data Officer
Stephana Patton, Ph.D., J.D. Chief Legal Officer
Joshua Stahl Chief Executive Officer

Funding Information

News

InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO

InterVenn Biosciences, the life sciences company pioneering glycoproteomic-based diagnostics, today announced that Joshua Stahl has been appointed as Chief Executive Officer to guide the company’s next phase of commercial growth.

InterVenn Scrubs Lease for Offices and Labs in South SF

Exit comes at a time with nearly 2M sf of life science space available on the Bay Area market, including both sublease and direct listings.

InterVenn Scrubs Lease for Offices and Labs in South SF

Exit comes at a time with nearly 2M sf of life science space available on the Bay Area market, including both sublease and direct listings.

Peninsula biotech InterVenn terminates South San Francisco lease amid flooded life sciences market

The company, which has raised close to $300 million, counts among its founders Carolyn Bertozzi, a Stanford University chemistry professor and 2022 winner of the Nobel Prize.

InterVenn Demonstrates Power of Its GlycoVision™ Platform In Advanced Adenoma and Colorectal Cancer

InterVenn Biosciences, the life science company pioneering glycoproteomics, presented new data at the 2023 Digestive Disease Week (DDW) annual conference, which was honored as a "Poster of Distinction". This data, generated by InterVenn’s novel, proprietary biomarker discovery platform, GlycoVision™, analyzed 575 retrospective samples and was able to achieve an overall sensitivity of 89% and specificity of 89% for predicting advanced adenoma (AA) and colorectal cancer (CRC).

Intervenn Biosciences to make Malaysia its regional hub

US-based clinical technology company InterVenn Biosciences has established Malaysia as the regional hub for delivery of its medical healthcare services and products in the Asean and Asia-Pacific regions.

InterVenn Biosciences quintuples funding with $201M for AI-powered cancer tests

In recent years, startups using artificial intelligence to develop liquid biopsy tests for cancer have attracted large hauls of medtech venture capital. In fact, four of the industry’s five largest VC rounds of 2020 went to companies developing AI platforms to improve cancer diagnosis and treatment.